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ABSTRACT: A biodegradable micellar drug delivery system with a pH-responsive sheddable 9 
PEG shell was developed using an acetal-linked poly(ethylene glycol)-block-polylactide (PEG-a-10 
PLA) copolymer and applied to the tumoral release of paclitaxel (PTX). The micelles with a 11 
diameter of ca. 100 nm were stable in PBS at pH 7.4, started shedding the shell and aggregating 12 
slowly at pH 6.5, and decomposed faster at pH 5.5. PTX-loaded micelles (M-PTX) with a drug 13 
loading of 6.9 wt% exhibited pH-triggered PTX release in simulated tumoral acidic environments 14 
corresponding to the extracellular and intracellular spaces. In vitro experiments showed that the 15 
micelles were non-cytotoxic to different cell lines, while M-PTX inhibited the proliferation and 16 
promoted the apoptosis of Hela cells. An in vivo study with Hela tumor-bearing mice indicated 17 
This document is the Accepted Manuscript version of a Published Work that appeared in final form in Biomacromolecules, copyright © American Chemical 
Society after peer review and technical editing by publisher. To access the final edited and published work see: http://dx.doi.org/10.1021/acs.biomac.7b00509
 2
that M-PTX efficiently inhibited tumor growth. Due to these properties, the PEG-a-PLA micellar 1 
system appears to have bright prospects as a tumor-targeting drug carrier. 2 
1. INTRODUCTION 3 
Nonspecific interactions between foreign materials and serum components in vivo is one of the 4 
main challenges for drug delivery systems used in cancer therapy, as it can lead to extensive 5 
aggregation and the rapid clearance of nanoparticles from circulation by the immune system.1 To 6 
overcome this challenge, a variety of hydrophilic polymers with stealth behavior have been 7 
developed to modify and stabilize drug delivery systems, among which poly(ethylene glycol) 8 
(PEG) is the most commonly applied non-ionic polymer because of its superior biocompatibility 9 
and water solubility.2-4 It is widely accepted that PEGylation is highly effective to minimize 10 
nonspecific interactions and to prolong the circulation time of nanoparticles in vivo since the 11 
1990s.5-10 Unfortunately, recent studies also indicated that PEGylation may significantly reduce 12 
nanoparticle uptake by tumor cells, leading to greatly reduced therapeutic efficacy.11, 12 It has 13 
been suggested that the cleavage of PEG chains from nanoparticles could facilitate cellular 14 
uptake.13-15 It was thus proposed that an ideal drug delivery system for cancer therapy should be 15 
colloidally stable in circulation, with a protective layer such as a shell of PEG chains, but allow 16 
shedding of the shell at the tumor site to promote cellular internalization.16-17 Shedding of the 17 
shell was also accompanied by dissociation of the particles in some cases, thus leading to more 18 
efficient drug release.18 The unique features of tumor tissues such as intracellular reduction, mild 19 
acidity, and the presence of specific proteins can be employed as triggers to induce PEG 20 
shedding from nanoparticles through appropriate material design.19-32  Zhong and coworkers 19-22 21 
thus developed a series of reduction-sensitive micelles with a sheddable shell for tumor-targeted 22 
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drug delivery based on disulfide-linked block copolymers. The disulfide bonds cleaved in 1 
response to the reductive environment in tumor cells, leading to rapid release of the drug. The in 2 
vivo performance demonstrated that these reduction-sensitive systems achieved significantly 3 
enhanced therapeutic efficacy and minimal side effects. The existence of a pH gradient between 4 
tumor tissues and the blood has also been considered an effective trigger to increase cell uptake 5 
and/or for the selective release of drugs in tumor tissues.23-29 For example, Meier et al.25 prepared 6 
a series of pH-responsive micelles from poly(dimethysiloxane)-block-poly(2-7 
(dimethylamino)ethyl methacrylate) for intracellular anticancer drug delivery. The carriers 8 
released doxorubicin in response to a decrease in pH from 7.4 to 5.5.  Meng and coworkers28 9 
reported pH-sensitive degradable polymersomes based on poly(ethylene glycol)-block-10 
poly(2,4,6-trimethoxybenzylidenepentaerythritol carbonate) for the controlled release of PTX 11 
and doxorubicin hydrochloride. Kataoka et al.29 prepared pH-sensitive polyion complex micelles 12 
from lactosylated PEG-siRNA conjugates and polyethylenimine (PEI) for siRNA delivery.  13 
While different nanoparticle systems with controlled shell-shedding and triggered drug release 14 
mechanisms have been developed for tumor treatment, their shell-shedding and drug release 15 
characteristics in the extracellular and intracellular spaces were not compared, especially for the 16 
pH-responsive systems, which limits the understanding of the behavior of these nanoparticles in 17 
vivo to some extent. In this work, a simple pH-sensitive micellar system with a sheddable shell 18 
was designed for tumor-targeted drug delivery based on block copolymers of PEG and PLA with 19 
an acid-labile acetal group (PEG-a-PLA; Scheme 1). Shedding of the PEG chains and drug 20 
release triggered by tumoral acidic conditions characteristic for both the extracellular and 21 
intracellular spaces were demonstrated. Furthermore, enhanced antitumor efficacy was achieved 22 
in vitro using the PTX-loaded pH-sensitive micelles (M-PTX) as compared with both their non-23 
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responsive counterpart and the free drug. It is well-known that good biocompatibility and 1 
biodegradability are important properties for drug delivery vehicles, and both PEG and PLA 2 
have been approved for biological use by the FDA.33-36 This efficient and safe micellar system 3 
therefore appears to have bright prospects in tumor treatment. 4 
 5 
 Scheme 1. Illustration of M-PTX preparation, pH-triggered PEG shell shedding and drug 6 
release in response to tumoral acidity in the extracellular and intracellular spaces. 7 
2. EXPERIMENTAL SECTION 8 
2.1 Materials, Cell lines and Animals 9 
All the chemicals employed in the procedures were purchased from Sigma-Aldrich and used as 10 
received unless otherwise noted. The lactide was recrystallized three times from dry ethyl 11 
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acetate, dried under vacuum, and stored at -20 ℃ until further use. The Sn(Oct)2 catalyst was 1 
first purified by distillation under reduced pressure and stored under nitrogen. The antitumor 2 
drug PTX and the fluorescent dye coumarin-6 (C6) were purchased from Aladdin Co. (Shanghai, 3 
China). Cell counting kits (CCK-8), DPAI and FITC were purchased from Dojindo Co. 4 
(Shanghai, China).  5 
The Hela cell line, human non-tumor hepatic cell line (L-02), and  human umbilical vein 6 
endothelial cell line (HUVEC) were used in this study. The information on their source, culture 7 
and incubation conditions is given in the Supporting Information.  8 
Nude female Balb/c mice (4 weeks old, body weight: 16 2 g) were purchased from Charles 9 
River Co. (Beijing, China). All the animal procedures were performed according to the research 10 
protocol approved by the Animal Experimentation Ethics Committee of Huazhong University of 11 
Science and Technology. 12 
2.2 Synthesis and characterization of PEG-a-PLA copolymer 13 
The method for the synthesis of the PEG-a-PLA block copolymer was developed by adapting a 14 
procedure reported by Hashimoto et al.37 for the synthesis of polyurethanes with degradable 15 
acetal linkages. A block copolymer with a non-cleavable block junction (PEG-b-PLA) was also 16 
synthesized. Gel permeation chromatography (GPC) and  1H NMR were employed to 17 
characterize the copolymers. The detailed synthetic procedures and characterization methods 18 
used are provided in the Supporting Information. 19 
2.3 Preparation, properties and characterization of PEG-a-PLA micelles 20 
Preparation of PEG-a-PLA micelles 21 
 6
PEG-a-PLA micelles were prepared as follows: A 1.0 wt % solution of PEG-a-PLA in N, N-1 
dimethylformamide (DMF) was prepared (typically 10 mg of copolymer in 1 g of DMF). 2 
Deionized water was added drop-wise to the solution with vigorous stirring at a rate of 1 mL/h, 3 
until a water content of 50 wt% was reached. The aggregates formed were then quenched by 4 
slowly adding the slightly turbid solution to 8 g of deionized water to freeze their morphology. 5 
The solution was subsequently dialyzed against deionized water for 3 days to remove all solvent 6 
residues. The concentration of the final solution was ca. 1.0 mg/mL. 7 
Self-assembly behavior investigation 8 
1H NMR analysis was employed to confirm the self-assembly of PEG-a-PLA. The critical 9 
micelle concentration (CMC) was measured by a fluorescence method using pyrene as a probe. 10 
Detailed protocols for these experiments can be found in the Supporting Information.  11 
Effects of heat treatment on the size distribution of PEG-a-PLA micelles 12 
A thermal treatment was employed to obtain micelles with a narrower size distribution. Briefly, a 13 
1.0 wt % solution of PEG-a-PLA in DMF was first prepared. Deionized water was added drop-14 
wise to the solution with vigorous stirring at a rate of 1 mL/h, until a water content of 10 wt% 15 
(100 μL) was reached. A 100 μL sample was withdrawn and the slightly turbid solution was 16 
heated to 60 ℃ with vigorous stirring for 10 min, until it became transparent. Then another 100 17 
μL aliquot of deionized water was added drop-wise at room temperature with vigorous stirring at 18 
a rate of 1 mL/h, to obtain a slightly turbid solution, at which point a second 100 μL sample was 19 
withdrawn, followed by a second heat treatment by the same procedure. Third and fourth 20 
samples were also withdrawn in that manner. All the samples were subjected to size distribution 21 
analysis by dynamic light scattering (DLS). 22 
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pH responsiveness of PEG-a-PLA micelles 1 
The size change of micelles in response to pH was monitored by DLS measurements. Briefly, 2 
micelles were subjected to treatments at pH 7.4, 6.5 and 5.5 in PBS, respectively, at 37 ℃ with a 3 
stirring speed of 200 rpm. At different time intervals, the size was determined by DLS. Size 4 
changes were also monitored for micelles incubated in the cell culture medium at 37°C in the 5 
presence of 10% FBS.  6 
Characterization 7 
Transmission electron microscopy (TEM) was employed to characterize the morphology of the 8 
micelles, using a Hitachi H-7000FA instrument operated at 100 kV and equipped with a CCD 9 
camera. Samples were prepared by dropping 10 μL of micellar solution onto a TEM grid 10 
followed by drying in air for 24 h. The hydrodynamic size of the micelles was determined at 11 
0.025 wt% concentration by DLS analysis on a Malvern Zetasizer Nano ZS90 (Malvern 12 
Instruments, Ltd., U.K.) equipped with a 4 mW He–Ne laser source (λ = 633 nm, scattering 13 
angle 90°). The micellar solutions were filtered through a 0.45 μm Millipore filter prior to 14 
analysis. 15 
2.4 Drug loading and simulated release in vitro 16 
Preparation and characterization of drug-loaded micelles 17 
PTX-loaded PEG-a-PLA micelles (M-PTX) were prepared by mixed self-assembly of the 18 
copolymer and PTX using a procedure similar to the preparation of the PEG-a-PLA micelles. 19 
Briefly, the copolymer (10 mg) and PTX (1 mg) were first dissolved in 1 g of DMF, followed by 20 
cycles of water addition, quenching and dialysis as described in Section 2.3. The concentration 21 
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of the final solution was ca. 1.0 mg/mL. PTX-loaded PEG-b-PLA micelles (Mb-PTX) were 1 
prepared by the same method, to be used as a control in the subsequent studies.  2 
 The entrapment efficiency (EE%) and drug loading capacity (DLC%) were determined by 3 
HPLC after dissolving M-PTX in acetonitrile.38 The HPLC system used consisted of a C-18 4 
column (4.6 mm × 250 mm) with 5 μm packing (Agilent Instruments, USA). The mobile phase 5 
was a mixture of acetonitrile and water in a ratio of 55:45 (v/v), at a flow rate of 1 mL/min. The 6 
sample (100 μL) was injected with an autoinjector (Agilent Instruments, USA), and the 7 
paclitaxel content was quantified by UV detection (227 nm, Agilent Instruments, USA). A 8 
calibration curve for paclitaxel was prepared in acetonitrile and used to determine the paclitaxel 9 
concentration. The EE% and DLC% were calculated using Equations (1) and (2), respectively. 10 
Entrapment Efficiency (EE%) = %100
feed in drug of Weight
micelles in drug of Weight
                 (1)  11 
Drug Loading Capacity (DLC%)= %100
micelles loaded-drug of Weight
micelles in drug of Weight
     (2) 12 
pH-triggered release of PTX from M-PTX 13 
 To simulate drug release in human blood and in the tumoral sites (both extracellular and 14 
intracellular spaces) in vitro, release profiles of PTX from M-PTX were obtained in PBS at pH 15 
7.4, 6.5 and 5.5, respectively, in the presence of 1 M sodium salicylate, by a dialysis method.39 16 
Sodium salicylate was used to achieve good sink conditions for PTX, as it can increase the 17 
aqueous solubility of PTX remarkably.40 Briefly, 1 mL of M-PTX solution was introduced into a 18 
dialysis tube (MWCO 3500) and dialyzed against 50 mL of PBS containing 1 M sodium 19 
salicylate at 37 ℃ with stirring at 100 rpm for 72 h. At preset time intervals (0, 1, 2, 4, 6, 8, 12, 20 
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16, 20, 24, 36, 48, 60, 72 h), 1 mL of the dialysis medium was withdrawn and an equal volume 1 
of fresh medium was added. The PTX release profiles from Mb-PTX and for free PTX under the 2 
same conditions were also studied as controls. The samples were analyzed by HPLC under the 3 
conditions described above.  4 
2.5 Cytotoxicity and cellular internalization of PEG-a-PLA micelles 5 
Cytotoxicity of PEG-a-PLA micelles 6 
The cytotoxicity of the PEG-a-PLA micelles was evaluated using the CCK-8 assay with Hela 7 
cells, L-02 cells, and HUVEC, respectively. Briefly, Hela cells and L-02 cells (1 ×104/well) were 8 
cultured in 96-well plates and incubated overnight. PEG-a-PLA micellar solution was then added 9 
to each well at different concentrations before incubation for 24, 48 and 72 h, respectively. For 10 
HUVEC, the cells were seeded at 5×103/well in 96-well plates and incubated overnight. PEG-a-11 
PLA micellar solution was then added to each well at different concentrations before incubation 12 
for 24, 72 and 120 h, respectively. This modified procedure was used because HUVEC cells are 13 
larger and proliferate more slowly than the two other cell lines. Then 10 μL of CCK-8 was added 14 
to each well. After incubation for 30 min at 37 ℃ in a humidified atmosphere containing 5% 15 
CO2, the absorbance was measured at 450 nm using a microplate reader (Thermo Fisher, USA). 16 
The cell viability was calculated using Equation (3) where ODS, ODB and ODN are the OD 17 
values for the samples, blank control and negative control, respectively. 18 
Cell viability=   %100

BODNOD
BODSOD                           (3) 19 
Cellular internalization of PEG-a-PLA micelles 20 
 10
To study the cellular internalization of PEG-a-PLA micelles, coumarin-6 labeled micelles (M-1 
C6) were prepared by mixed self-assembly of the copolymer and C6 through procedures similar 2 
to those described for M-PTX in Section 2.4. To mimic the extracellular environment of tumor 3 
tissues, M-C6 samples were subjected to treatment with PBS at pH 6.5 for different time periods 4 
before use. Hela cells (5 ×104/well) were seeded on 8-chamber slides (Lab Tek Ⅱ, Thermo 5 
Fisher) and incubated overnight. Then the pretreated M-C6  (0.2 mg/mL) were incubated with 6 
the cells for 30 min. After removing the M-C6-containing medium the cells were washed with 7 
PBS three times, stained with DAPI for 15 min, and washed three times with PBS. The samples 8 
were imaged with a confocal laser scanning microscope (Olympus, FV1000). The cellular 9 
internalization of M-C6 without treatment, C6-loaded non-responsive PEG-b-PLA micelles (Mb-10 
C6) and of free C6 were also investigated as controls.  11 
2.6 In vitro antitumor assay 12 
Cytotoxicity of M-PTX to Hela cells 13 
Hela cells were seeded in 96-well plates at 1 ×104 cells per well and incubated at 37 ℃ 14 
overnight. Various formulations including M-PTX, Mb-PTX and free PTX were then added to 15 
the cells corresponding to different PTX concentrations. It should be noted that the pH of the 16 
culture medium was adjusted to 6.5 with 0.1 M HCl before the treatment, to mimic the 17 
extracellular environment in tumor tissues. After 48 h of incubation, the cytotoxicity of each 18 
formulation was evaluated by the CCK-8 assay as described in Section 2.5. The cytotoxicity of 19 
these PTX formulations to Hela cells was also evaluated in normal culture medium (i.e. culture 20 
medium without pH adjustment). 21 
 11
Cell cycle analysis 1 
Cell cycle analysis was performed using propidium iodide (PI; Keygentec, China) staining to 2 
measure the DNA content and distribution of cells in various cell cycle phases. Hela cells (30 3 
×104/well) were seeded in 6-well plates and incubated overnight, followed by treatment with M-4 
PTX, Mb-PTX and PTX (0.1 g /mL) for 48 h. Cells without treatment were used as control. 5 
Moreover, to mimic the extracellular environment in tumor tissues,  the treatment with M-PTX 6 
and Mb-PTX was also used for Hela cells at pH 6.5 (the pH of the culture medium was adjusted 7 
to 6.5 with 0.1 M HCl before treatment). The Hela cells were harvested and suspended in cold 8 
PBS, and fixed with 90% cold ethanol at -20 ℃ overnight. The cells were then resuspended in 9 
PBS containing RNaseA (Solarbio, China) and incubated at 37 ℃ for 40 min to remove the 10 
RNA. Finally, the cells were stained with PI at 4 ℃ for 20 min in the dark. The data were 11 
calculated using the Cell Quest and Modfit software packages to determine the cell cycles.    12 
 Cellular apoptosis assay 13 
The Hela cells were subjected to treatment with M-PTX, Mb-PTX and PTX (0.1 g /mL) for 48 14 
h as described above.  The cells were sequentially washed, trypsinized, washed and centrifuged. 15 
Cellular apoptosis was performed on a flow cytometer (BD FACSCalibur, USA) using the 16 
Annexin V-FITC (Annexin V) and PI detection kits, according to the manufacturers' instructions.   17 
To further study the mechanism of antitumor activity of M-PTX, the gene expression assay was 18 
performed for M-PTX-treated Hela cells. The protocol used is provided in the Supporting 19 
Information.                                                                                                                                                 20 
2.7 In vivo experiments 21 
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In vivo and ex vivo imaging 1 
Subcutaneous tumors were developed in female nude mice by the subcutaneous injection of 2 2 
×106/0.2 mL Hela cells in the axillary region. The mice were used for the study when the tumor 3 
grew to approximately 200 mm3. 4 
C6 and M-C6 were administered via tail vein injection at the same concentration of C6. For in 5 
vivo imaging 0, 6, 24 and 48 h post-injection, the tumor-bearing mice were anesthetized with 6 
isoflurane (RWD Life Science, China) and the fluorescence images were captured with a 1-s 7 
exposure time using a small animal in vivo fluorescence imaging system (IVIS Lumina XRMS 8 
II, PerkinElmer, USA). The mice were sacrificed at 24 and 48 h post-injection and their tumor 9 
tissues were subjected to ex vivo fluorescence imaging using frozen sections by confocal 10 
fluorescence microscopy (Olympus FU1000, Japan).   11 
Anti-tumor effect 12 
The tumor-bearing mice were randomly divided into three groups of five mice each. PTX and M-13 
PTX were administered via tail vein injection at the same PTX concentration (the dose was 5 14 
mg/kg) every 3 days over 36 days. The tumor volume and body weight of the mice were 15 
measured 3 days after each injection, immediately before the next injection. The mice were 16 
sacrificed and the tumor tissues were harvested and fixed in 4% paraformaldehyde 3 days after 17 
the last injection. For histopathological analysis, tumor paraffin sections were stained with 18 
hematoxylin and eosin (HE, Servicebio, China). Immunohistochemical staining with antibodies 19 
against proliferating cell nuclear antigen (PCNA) was done to evaluate the proliferation of tumor 20 
cells. The frozen tumor sections were used to assess apoptosis by the method of terminal 21 
deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL). 22 
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2.8 Statistical analysis 1 
Descriptive data are expressed as the arithmetic mean value ± standard deviation (SD). All the 2 
quantitative results were obtained from at least triplicate samples. Data on cytotoxicity of 3 
different PTX formulations were analyzed statistically using Student’s t test. P values of 0.05 or 4 
less were considered significant. 5 
3. RESULTS AND DISCUSSION 6 
3.1 Synthesis and characterization of the PEG-a-PLA and PEG-b-PLA copolymers 7 
The synthesis of the copolymers was achieved according to the reaction schemes provided in 8 
Figure 1A. The success of the chain extension reaction from the PEG monomethyl ether (mPEG) 9 
substrate was confirmed by the presence of a single peak in the GPC analysis traces for the block 10 
copolymers, shifted to a higher molecular weight (lower elution volume) relatively to the mPEG 11 
substrate (Figure 1B). 12 
The chemical composition of the copolymers was determined by 1H NMR analysis, with 13 
typical spectra shown in Figure 1C for both copolymers. In the 1H NMR spectra of both 14 
copolymers, peaks were present at 1.59, 5.24, 3.75 and 3.4 ppm. The peaks at 1.59 and 5.24 ppm 15 
are assigned to protons in -CH3 groups and -CH- groups of the PLA chains, respectively, and the 16 
peaks at 3.75 and 3.4 ppm correspond to the protons in the PEG backbone and the methyl end 17 
group, respectively. As compared with the spectrum for PEG-b-PLA, the extra peaks at 4.7 and 18 
1.2 ppm appearing in the spectrum for PEG-a-PLA are assigned to the -CH3 and -CH- protons in 19 
the acetal group linking the PLA and PEG blocks.41 The presence of the PLA and PEG 20 
components in the 1H NMR spectrum further confirms the success of the procedures developed 21 
 14
for the synthesis of the PEG-a-PLA and PEG-b-PLA copolymers. The results of the GPC and 1 
NMR analyses for the block copolymers synthesized are summarized in Table 1. 2 
 3 
Figure 1. Synthesis and characterization of the copolymers: A. Synthetic routes for PEG-a-PLA 4 
and PEG-b-PLA; B. GPC traces for (from right to left) mPEG with Mn ~ 5000, PEG-a-PLA and 5 
PEG-b-PLA; C. 1H NMR spectra for (top) PEG-b-PLA and (bottom) PEG-a-PLA. 6 
Table 1. Results of GPC and NMR analysis for PEG-a-PLA and PEG-b-PLA. The mPEG block 7 
had Mn = 5000 and Mw/Mn = 1.04.  8 
Copolymer  Mn Mw/Mn mol% PLA 
PEG-a-PLA 11000 1.07 26 
 15
PEG-b-PLA 15000 1.16 45 
 1 
 2 
3.2 Preparation and characterization of PEG-a-PLA micelles 3 
The self-assembly of the PEG-a-PLA copolymer into micellar aggregates was induced by slow 4 
addition of a solvent selective for the PEG block (water) to a solution in a good solvent for both 5 
blocks (DMF). Under these conditions the hydrophobic PLA chain segments are expected to 6 
form the core, while the shell consists of hydrophilic PEG chain segments (Scheme 1).  7 
The as-prepared PEG-a-PLA micelles, observed by TEM, had a spherical topology (Figure 2 8 
A, B). It should be noted that Figure 2A shows the micelles prepared without heat treatment, 9 
while Figure 2B presents the micelles prepared with a one-cycle heat treatment. Interestingly, the 10 
micelles in Figure 2A show a non-uniform size ranging from tens of nanometer to hundreds of 11 
nanometer, while the latter shows micelles with a much more uniform size. This difference was 12 
also reflected in the DLS results given in Figure 2C: A unimodal peak with a hydrodynamic 13 
diameter around 100 nm and a polydispersity index of 0.12 was found in the intensity 14 
distribution plots for micelles prepared with one cycle of heat treatment, while two populations 15 
around 50 and 500 nm were observed for the micelles without treatment. A likely explanation for 16 
this is re-equilibration of the samples under closer to equilibrium conditions, as a result of 17 
gradual temperature changes. It should also be noted that additional heat treatment rounds did 18 
not yield significant differences in the size and size distribution of the micelles, which implies 19 
that the temperature variations led to more gradual variations in solvent quality in comparison to 20 
the slow addition of a non-solvent to the copolymer solution. The micelles prepared with a one-21 
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cycle heat treatment were used for the subsequent studies throughout this paper, because 1 
nanoparticles in this size range (around 100 nm diameter) with a low polydispersity are believed 2 
to be optimal for prolonged circulation as well as balanced accumulation and penetration in 3 
tumors.42 4 
In addition, the self-assembly of PEG-a-PLA copolymers into micellar aggregates was verified 5 
by 1H NMR analysis through the measurement of diffusion constants (Figure S1 and Table S1). 6 
Moreover, the CMC of PEG-a-PLA was measured to be 6.3×10-3 mg/mL by fluorescence 7 
spectroscopy (Figure S2). Detailed results and discussion of these topics can be found in the 8 
Supporting Information. 9 
 10 
Figure 2. Topology and size of the micelles: A. TEM image for PEG-a-PLA micelles without 11 
heat treatment. Scale bar: 1 µm; B. TEM image for PEG-a-PLA micelles after one cycle of heat 12 
treatment. Scale bar: 1 µm; C. Size distribution from DLS of PEG-a-PLA micelles with and 13 
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without heat treatment. The size is expressed as the hydrodynamic diameter (d, nm). HT: heat 1 
treatment; D. Change in hydrodynamic diameter (d, nm) of PEG-a-PLA micelles in PBS 2 
solutions at different pH by DLS.  3 
3.3 pH-induced size changes of PEG-a-PLA micelles  4 
The pH responsiveness of the PEG-a-PLA micelles was investigated by monitoring size changes 5 
in PBS at different pH (i.e. 7.4, 6.5 and 5.5) as a function of time using DLS. It can be seen in 6 
Figure 2D that the particle size maintained almost unchanged (around 100 nm) after treatment in 7 
PBS at pH 7.4 for up to 24 h, confirming that the micelles were stable in this environment. When 8 
the pH was decreased to 6.5, it was found that the size of the micelles was essentially unchanged 9 
after 2 h of treatment, but tended to increase with a broader distribution after 6 h,  which shows 10 
that the micelles became unstable, presumably due to partial PEG chain shedding and aggregate 11 
formation by the PLA cores.  The instability of the micelles became more obvious, with the 12 
formation of more and larger aggregates, after 24 h of treatment in PBS at pH 6.5. It can also be 13 
seen in Figure 2D that the size of the particles increased more rapidly in PBS at pH 5.5 as 14 
compared to pH 6.5. This implies that the micelles were destabilized and formed aggregates 15 
more rapidly as a result of the accelerated hydrolysis of acetal bonds at the lower pH. It has been 16 
similarly reported that fast aggregation could be induced in the presence of glutathione or 17 
dithiothreitol for redox-sensitive shell-sheddable micelles such as poly(ethylene glycol)-SS-18 
poly(ε-caprolactone) (PEG-SS-PCL)21 and poly(ethylene glycol)-SS-poly(2,4,6-19 
trimethoxybenzylidene-pentaerythritol carbonate) (PEG-SS-PTMBPEC).22 The stability of the 20 
micelles in cell culture medium at 37°C with 10% FBS was also studied. No significant changes 21 
in size were observed for the micelles after incubation for 24 h (Figure S3). The results obtained 22 
therefore suggest that the PEG-a-PLA micelles should be stable in human blood, while the PEG 23 
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shell would become sheddable in response to the mildly acidic tumoral environment, especially 1 
in the intracellular endosome. 2 
3.4 Drug loading and simulated release in vitro 3 
A calibration curve relating the paclitaxel concentration X (µg/mL) in acetonitrile to the response 4 
was obtained as Y = 0.00299 X - 8.73 × 10-4 (R2 = 0.998, where Y presents the HPLC peak area, 5 
in arbitrary units). Using Equations (1) and (2) provided in Section 2.4 in combination with the 6 
calibration curve, the entrapment efficiency (EE%) and drug loading capacity (DLC%) of the 7 
PEG-a-PLA micelles were calculated to be 68.7% and 6.9 wt%, respectively. 8 
The in vitro PTX release profiles from M-PTX at different pH are compared in Figure 3. It can 9 
be seen that both M-PTX and Mb-PTX displayed sustained PTX release behavior over a period 10 
of 72 h, with cumulative release of 45% and 38%, respectively, after 72 h at pH 7.4. The slightly 11 
lower release for Mb-PTX over M-PTX at pH 7.4 may be due to the larger size of Mb-PTX 12 
micelles (around 200 nm). The influence of particle size on the drug release rate was investigated 13 
previously.43 However, much faster and more effective PTX release was observed for M-PTX at 14 
pH 6.5 as compared to Mb-PTX. The cumulative release of PTX from M-PTX reached 48% after 15 
24 h at pH 6.5 and increased to 70% after 72 h, while Mb-PTX did not show as much change at 16 
pH 6.5 as compared with pH 7.4, with cumulative PTX release of 25% and 39% after 24 and 72 17 
h, respectively. Moreover, at pH 5.5 the PTX release from M-PTX was further accelerated as 18 
compared to pH 6.5. The cumulative release of PTX under these conditions reached 70% and 90 19 
% after 24 and 72 h, respectively.  As a control, the free PTX solution showed a burst release of 20 
PTX with cumulative release over 90% after 12 h, irrespective of the pH. The increased drug 21 
release rate and improved cumulative release from M-PTX at pH 6.5 and 5.5 are attributed to the 22 
 19
acid-triggered PEG chain shedding from the micelles. Furthermore, drug release was increased at 1 
the lower pH as a result of accelerated PEG chain shedding. These pH-triggered drug release 2 
profiles for M-PTX suggest that the PEG-a-PLA micelles could serve as efficient vehicles for 3 
tumor-targeted drug delivery. 4 
 5 
Figure 3. Release profiles for PTX from M-PTX, Mb-PTX and free PTX in PBS solutions at 6 
different pH in the presence of 1 M sodium salicylate at 37 ℃. 7 
3.5 Cellular toxicity of blank micelles  8 
The cytotoxicity of blank PEG-a-PLA micelles was evaluated with different cell lines including 9 
Hela cells, L-02 cells and HUVEC. Cell viability, calculated using Equation (3) given in Section 10 
2.5, is provided in Figure 4. It is clear that the micelles were not toxic to Hela cells (Figure 4A), 11 
as cell viability was higher than 100% after incubation for 72 h at a micellar concentration of 200 12 
μg/mL. No obvious changes in Hela cell viability were observed for different micellar 13 
concentrations (from 2 to 200 μg/mL) and incubation periods (24, 48, 72 h). The cytotoxicity of 14 
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blank PEG-a-PLA micelles to L-02 cells and HUVEC is depicted in Figure 4B and Figure 4C, 1 
respectively. Again, the micelles showed no obvious cytotoxicity to L-02 cells and HUVEC for 2 
different concentrations (from 2 to 200 μg/mL) and incubation times (24, 48, 72 h for L-02 cells; 3 
24, 72, 120 h for HUVEC) with a cell viability of over 90%. These results indicate that the PEG-4 
a-PLA micelles are highly biocompatible and could be useful for biomedical applications. 5 
3.6 Cellular internalization of fluorescently labeled micelles 6 
The cellular internalization of the PEG-a-PLA micelles was studied using C6-labeled micelles 7 
(M-C6). It can be seen from Figure 4D that the fluorescent dye encapsulated in M-C6 and the 8 
C6-labeled non-responsive micelles (Mb-C6) entered the cytoplasm of Hela cells more efficiently 9 
than free C6. This suggests that encapsulated C6 entered the cells through a carrier-mediated 10 
endocytosis pathway, while free C6 was internalized more gradually by diffusion. This is 11 
consistent with previous studies in which the authors claimed that encapsulated drugs entered the 12 
cells through carrier-mediated endocytosis, followed by intracellular release.44, 45 It is interesting 13 
to note that the cellular internalization efficiency of M-C6 subjected to treatment with PBS at pH 14 
6.5 for 2 and 6 h was enhanced slightly as compared with M-C6 without treatment, while it 15 
decreased markedly for M-C6  incubated at pH 6.5 for 24 h. This can be explained as follows: 16 
The micelles were slowly destabilized at pH 6.5, with a relatively low extent of  PEG chain 17 
shedding after 2 and 6 h, that was insufficient to form large aggregates but facilitated the cellular 18 
uptake of the particles to some extent. It has been indeed suggested that PEG chain shedding can 19 
facilitate the cellular internalization of nanoparticles.13-15 Wang et al.13 thus reported tumor-pH 20 
responsive polymeric nanoparticles based on block copolymers of PEG and poly(D,L-lactic 21 
acid). They concluded that both the release of the PEG corona and an increase in zeta potential of 22 
the nanoparticles could facilitate cellular uptake. In the current case, the C6 molecules were 23 
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presumably also delivered into the cells mainly through carrier-mediated endocytosis. In 1 
contrast, the extent of PEG chain shedding was much increased after 24 h of treatment and large 2 
aggregates formed, which is expected to impede cellular uptake.43 In that case the C6 molecules 3 
first diffused out of the aggregates and entered the cells similarly to the free dye. It is known that 4 
the retention time of nanoparticles in the extracellular environment before cellular uptake is 5 
normally rather short (less than 6 h).46, 47 Therefore, it is believed on the basis of these results 6 
that the PEG-a-PLA micelles loaded with drug should be internalized by tumor cells in vivo 7 




Figure 4. Cytotoxicity of blank PEG-a-PLA micelles determined by CCK-8 analysis with 2 
different cell lines: A. Hela cells; B. L-02 cells; C. HUVEC; D. Cellular internalization of PEG-3 
a-PLA micelles fluorescently labeled with C6. M-C6 represents C6-labeled PEG-a-PLA micelles 4 
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without treatment; Mb-C6 represents C6-labeled non-responsive PEG-b-PLA micelles; “M-C6 1 
pH 6.5 x h” denote the C6-labeled PEG-a-PLA micelles subjected to treatment with PBS at pH 2 
6.5 for x h. Scale bar: 50 μm. 3 
3.7 Anti-tumor efficacy in vitro 4 
Cellular proliferation assay 5 
The in vitro cytotoxicity of M-PTX to Hela cells was evaluated by the CCK-8 assay. To simulate 6 
the extracellular tumor space, the pH of the culture medium for Hela cells was adjusted to 6.5 7 
with 0.1 M HCl before treatment with various PTX formulations. It was first verified that pH 6.5 8 
did not affect cell viability, in that cell viability was as high as in normal culture medium (Figure 9 
5A). Similar treatment and results were reported in the literature, where the authors demonstrated 10 
that even pH 5.8 did not affect tumor cell viability.48 It can been seen in Figure 5A that the 11 
cytotoxicity of all the PTX formulations increased with the PTX concentration. It is worth noting 12 
that the cytotoxicity of M-PTX at pH 6.5 was significantly enhanced as compared to Mb-PTX 13 
and free PTX when the PTX concentration was over 0.1 µg/mL, while  the cytotoxicity of M-14 
PTX under normal conditions was only slightly higher than for Mb-PTX and free PTX when the  15 
PTX concentration was 0.4 µg/mL. The enhanced cytotoxicity of M-PTX at pH 6.5 over Mb-16 
PTX and free PTX could be due to the increased cellular internalization and pH-triggered rapid 17 
intracellular drug release.  18 
To further study the effects of M-PTX on cellular proliferation, the cell cycle progression of 19 
Hela cells treated with the different PTX formulations for 48 h was analyzed by flow cytometry. 20 
According to Figure 5B, in comparison with the control, the PTX formulations (M-PTX, Mb-21 
PTX and free PTX ) in normal culture medium led to a remarkable increase in the accumulation 22 
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of G2 phase cells, which increased from 13.2% (control) to 40.5% (M-PTX), 22.3% (Mb-PTX) 1 
and 29.4% (free PTX), indicating that these PTX formulations affected cellular proliferation by 2 
the same mechanism. It is well-known that PTX can induce cell cycle arrest in the G2 phase of 3 
mitosis, resulting in the restraint of cell proliferation.49, 50 The superior proliferation inhibition for 4 
M-PTX is ascribed to increased cellular internalization (over free PTX) and fast intracellular 5 
drug release (as compared to Mb-PTX). Moreover, it should be noted that M-PTX at pH 6.5 6 
yielded further increase in accumulation of G2 phase cells as compared to the normal culture 7 
medium. This could be explained by enhanced internalization of the pH-sensitive micelles at pH 8 
6.5 over the normal culture medium, as described in Section 3.6.  9 
Cellular apoptosis assay 10 
The induction of Hela cell apoptosis by the various PTX formulations was quantified by flow 11 
cytometry. It was found that M-PTX at pH 6.5 gave the highest percentage of cellular apoptosis 12 
(including early and late apoptosis) as compared to the other formulations (Figure S4). In 13 
addition,  the gene expression assays indicated that M-PTX induced cellular apoptosis in the 14 
same manner as free PTX, which is by promoting the expression of caspase-3 while inhibiting 15 
the expression of Caspase, PCNA, B-cell leukemia/lymphoma-2 (BCL-2) (Figure S5).  The 16 
enhanced cellular apoptosis caused by M-PTX at pH 6.5 can be likewise attributed to the 17 
synergistic effect of enhanced cellular internalization and pH-triggered intracellular drug release.  18 
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 1 
Figure 5. In vitro antitumor activity of M-PTX for Hela cells. A. Cytotoxicity of the different 2 
PTX formulations determined by CCK-8 analysis. Significant differences compared with Mb-3 
PTX *P < 0.05. B. Cell cycle distributions of cells treated with the different PTX formulations 4 
for 48 h.  5 
3.8 Anti-tumor efficacy in vivo 6 
Tumor targeting efficacy 7 
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The in vitro drug release and cellular internalization studies demonstrated that the micelles could 1 
be useful as carriers for drug delivery with pH responsiveness. To further evaluate the potential 2 
of the micelles as anti-tumor drug carriers, in vivo tumor targeting efficacy was investigated with 3 
a living fluorescence imaging system. The mice were injected through the tail vein with M-C6, 4 
or with C6 as a control. As shown in Figure 6A, the control group yielded a decreasing 5 
fluorescence intensity in the tumor area with the post-injection time. The fluorescence intensity 6 
in the tumor area was rather low at 6 h post-injection and decreased rapidly over the next 18 h, 7 
because of the animal metabolism. After 48 h post-injection, the fluorescence in the tumor area 8 
almost completely disappeared for the control group. In contrast, the fluorescence intensity in the 9 
tumor area was much higher for the mice injected with M-C6 than for the control group. It was 10 
also found that fluorescence accumulation in the tumor area increased with time within 24 h 11 
post-injection. The fluorescence intensity in the tumor area for both groups is quantified in 12 
Figure 6B. It can be seen that the radiation efficiency of fluorescence in the tumor area for the 13 
M-C6 group was approximately six times as high as for the control group at 24 h post-injection. 14 
The differences in C6 accumulation in the tumor area between the M-C6 and control groups was 15 
also reflected in the fluorescence images of tumor sections at 24 and 48 h post-injection, shown 16 
in Figure 6C. It is apparent that C6 accumulation in tumor tissues was much higher in the M-C6 17 
group than in the control group after 24 h, while the difference between the two groups became 18 
smaller after 48 h because of the animal metabolism, which is in agreement with the results of 19 
Figures 6A and 6B. The above results indicate that the micelles could significantly prolong the 20 
circulation time of C6 in vivo with the protective effect of PEG, and promote accumulation in the 21 
tumor area through a passive targeting mechanism, that is mainly the enhanced permeability and 22 
retention (EPR) effect. However it should be clarified that M-C6 is not expected to show tumor-23 
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specific targeting ability beyond the EPR effect, since no targeting ligands were employed in the 1 
present micellar system.   2 
 3 
Figure 6. Tumor-targeting efficacy of M-C6. A. In vivo time-dependent fluorescence images 0, 4 
6, 24 and 48 h after the administration of M-C6 and free C6. The color bar (from red to blue) 5 
indicates changes in fluorescence radiation efficiency from high to low. B. Quantification of the 6 
tumor-targeting characteristics of M-C6 and free C6. C. Fluorescence images for tumor sections 7 
at 24 and 48 h post-injection of M-C6 and free C6. Scale bar: 100 μm. 8 
Antitumor efficacy 9 
Due to the prolonged circulation time and enhanced tumor localization, M-PTX was expected to 10 
have good antitumor efficacy in vivo. Hela tumor-bearing mice were used to evaluate the in vivo 11 
antitumor potential of M-PTX. The measurements of tumor volume and body weight of the mice 12 
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treated with successive tail vein injections of different PTX formulations are shown in Figure 1 
7A. It can be seen that from the fifth dose to the last, the M-PTX and PTX groups displayed 2 
smaller tumor volumes as compared to the control group, while the M-PTX group showed the 3 
smallest tumor volumes. Moreover, the differences between these groups became more 4 
significant as the treatment time increased. These results reveal that the pH-responsive micelles 5 
enhance the antitumor efficacy of PTX. In addition, the body weight of mice showed no 6 
significant differences among the groups throughout the treatment. Pictures of the final tumors 7 
harvested from the mice after the treatments, and images of HE-stained tumor sections are 8 
presented in Figure 7B. Tumor cells with a spherical or spindle shape were observed in the 9 
control group, suggesting good growth of the tumor. On the contrary, cellular necrosis and dead 10 
cells with condensed nuclei could be seen in the PTX and M-PTX groups. Moreover, the largest 11 
number of dead cells with condensed nuclei was observed in the M-PTX group, which provides 12 
substantial evidence for enhanced antitumor efficacy of PTX combined with the micelles.51 To 13 
further investigate the in vivo antitumor efficacy of M-PTX, an immunohistochemical study 14 
including TUNEL assay and PCNA expression was also performed with the tumor sections 15 
(Figure 7C). In agreement with the results for the tumor growth rate and the HE-stained tissue 16 
observations, the M-PTX group presented the largest number of TUNEL-positive tumor cells 17 
and the lowest expression of PCNA, which means that the M-PTX treatment was most efficient 18 
at inhibiting the proliferation and inducing death in tumor cells.52  19 
There have been many reports on shell-sheddable micellar systems for tumor-targeted drug 20 
delivery in recent years, among which a few carefully designed systems exhibited superior 21 
antitumor efficacy in vivo. A good example of this is cRGD-functionalized reduction-responsive 22 
shell-sheddable disulfide-linked PEG-SS-PCL block copolymers for the intracellular delivery of 23 
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doxorubicin developed by Zhong and coworkers.53 This system displayed efficient tumoral 1 
accumulation and fast drug release in tumor cells, with superior therapeutic outcomes for human 2 
glioma xenografts in vivo. Additionally, with the non-cRGD-functionalized PEG-SS-PCL 3 
micellar system, remarkable antitumor efficacy in vivo could be accomplished by injecting 4 
exogenous vitamin C when tumor accumulation of the drug-loaded micelles reached their highest 5 
level. This is because vitamin C acted as a reducing agent, which triggered the rapid extracellular 6 
drug release from the micelles.54 In the current investigation, a simple pH-sensitive PLA-a-PEG 7 
micellar system with a sheddable shell was designed for tumor-targeted drug delivery. The shell-8 
shedding and drug release behaviors of M-PTX in simulated tumoral extracellular and 9 
intracellular environments were compared systematically. The in vivo performance demonstrated 10 
that M-PTX could efficiently inhibit tumor growth. The possible reasons for the enhanced 11 
antitumor efficacy of M-PTX over free PTX could be explained as follows: Firstly, the PEG 12 
shell should stabilize the particles and prolong their circulation time in the bloodstream, leading 13 
to enhanced tumoral accumulation by passive targeting via the EPR effect. Secondly, after the 14 
particles arrive at the tumor sites, partial PEG shedding is induced by the mildly acidic 15 
extracellular space (pH 6.5-7.2), which can promote cellular internalization of the particles to 16 
some extent (with a small amount of drug released in the extracellular space). Finally, the shell 17 
of the particles degrades extensively, with efficient drug release triggered by the lower pH (5.0-18 
6.0) in the endosome, thus achieving a high antitumor efficacy. However, it is admittedly a 19 
limitation of this work that the relevance of pH-sensitive shell-shedding in vivo was not fully 20 





Figure 7. In vivo antitumor efficacy of M-PTX. A. Changes in the tumor volume and body 2 
weight of the Hela tumor-bearing nude mice receiving intravenous injections of M-PTX and free 3 
PTX. B. Representative images for HE-stained tumor sections after treatment with M-PTX and 4 
free PTX. Scale bar: 100 μm. C. PCNA and TUNEL assays of tumor sections after treatment 5 
with M-PTX and free PTX. Scale bar: 100 μm. 6 
4. CONCLUSIONS 7 
 31
A PEG-a-PLA micellar system with pH responsiveness was developed, characterized and 1 
evaluated in vitro and in vivo as carrier for tumor-targeted drug delivery. The spherical micelles, 2 
with an average diameter of ca. 100 nm, were stable in PBS at pH 7.4, but responded to mildly 3 
acidic conditions with more rapid drug release. It was found that the drug-loaded micelles 4 
efficiently inhibited cellular proliferation and promoted the apoptosis of Hela cells in vitro, and 5 
inhibited tumor growth in vivo without obvious harmful side effects. The enhanced antitumor 6 
efficacy of PTX-loaded micelles over free PTX is attributed to a synergistic effect of several 7 
factors including a significantly prolonged circulation time, enhanced cellular internalization, 8 
and pH-triggered intracellular drug release. Since both PEG and PLA are FDA-approved for 9 
biological use due to their excellent biocompatibility and biodegradability, the pH-responsive 10 
PEG-a-PLA micellar system has great prospects in clinical applications as drug carriers for 11 
cancer treatment. 12 
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